These data implicate Stat4 in inflammatory pathways associated with metabolic syndrome, atherosclerosis, neuroinflammation, and potentially AD, suggesting that treatments that suppress activity of this transcription factor or downstream pathway components could reduce AD risk in diabetics, and in normal aging. The gene discussed is STAT4; the disease is atherosclerosis.